The Affimer technology represents renewable binding reagents for molecular biology, which provides research scientists and industry with an alternative to the recently criticised use of animal-produced antibodies.

Open science and consensus antibody validation protocols can identify high-quality, renewable antibodies for the ~50% of the human proteome currently covered, enabling robust and reproducible biomedical research.

There is an ongoing need for researchers and all stakeholders to better understand issues surrounding antibody characterization to improve the quality and reproducibility of research that employs these reagents.

3D culture of breast cancer in biologically relevant ECM potentiates the growth-inhibitory effects of unacylated ghrelin and AZP-531, and clinical response may be predictable based on a MAPK gene signature.

Live cell tracking of labeled DNA reveals that replisome loading rather than DNA synthesis decreases the chromatin motion during S-phase in human cells.

The Mtgr1 protein promotes the maintenance of pluripotency and germ cell formation via its interaction with the stem cell regulator Prdm14.

Protocols that greatly simplify the use of nanobodies in fluorescence imaging and affinity purification have been developed.

An analysis of peer review and funding outcomes of NIH research applications shows that funding disparities of topics preferred by African American Black investigators are not due to peer review preferences or biases.

Naive hPSCs can readily give rise to human trophoblast stem cells, thus demonstrating their extraembryonic lineage potential and providing a new model system to study human trophectoderm specification.

Parallel pathways of xylose metabolism identified in fungi that grow on plants can be used in yeast to promote hemicellulose conversion to biofuels.